Critics of the EU MDR have long cautioned that certain new requirements, such as tightening up clinical evidence rules for high-risk products, could lead to some manufacturers leaving the European market altogether due to the costs of running clinical trials.
Medical devices made for use in children or to treat orphan conditions are “particularly vulnerable” to market withdrawals and action...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?